News - Neurological

Filter

Current filters:

Neurological

Popular Filters

73 to 97 of 914 results

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

Pfizer’s ALO-02 meets efficacy endpoint in Ph III

23-01-2014

US pharma behemoth Pfizer has released top-line results from a Phase III study of ALO-02 (oxycodone HCl…

ALO-02NeurologicalPfizerPharmaceuticalResearch

Lundbeck’s Brintellex available in US pharmacies for depression

Lundbeck’s Brintellex available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

NICE recommends Sanofi’s Aubagio as new treatment option for MS

NICE recommends Sanofi’s Aubagio as new treatment option for MS

22-01-2014

In final guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

AubagioBiotechnologyGenzymeNeurologicalNorthern EuropePricingRegulationSanofiUK

NuPathe accepts Teva’s higher counter bid, rejecting Endo offer

21-01-2014

Israel-based Teva Pharmaceutical Industries seems set to bag ownership of US drugmaker NuPathe), which…

Endo Health SolutionsMergers & AcquisitionsNeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Santhera's Raxone granted temporary use in France

21-01-2014

Switzerland-based Santhera Pharmaceuticals (SIX: SANN) announced today that the French National Agency…

FranceNeurologicalPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Disappointing results for Roche in Phase III schizophrenia studies

Disappointing results for Roche in Phase III schizophrenia studies

21-01-2014

Swiss drug major Roche (ROG: SIX) has revealed disappointing results from two Phase III studies of its…

bitopertinNeurologicalNorthern EuropePharmaceuticalResearchRoche

Mundipharma strengthens patent rights for heroin substitution in deal with Phoenux

20-01-2014

Privately-held drugmaker Mundipharma International has acquired exclusive global rights to a family of…

MorphineMundipharmaNaloxoneNeurologicalPatentsPharmaceuticalPhoenux

Record $122 million increase for Alzheimer's disease passed by US Congress

17-01-2014

An unprecedented $122 million increase for Alzheimer's research, education, outreach and caregiver support…

FinancialHealthcareNeurologicalNorth AmericaPharmaceuticalPoliticsResearchUSA

FDA recommends high-dose acetaminophen combo drugs be discontinued

FDA recommends high-dose acetaminophen combo drugs be discontinued

16-01-2014

The US Food and Drug Administration is recommending health care professionals discontinue prescribing…

NeurologicalNorth AmericaPharmaceuticalRegulationUSA

Jazz Pharma in $397 million deal with Aerial for narcolepsy drug ADX-NO5

14-01-2014

Ireland-headquartered drugmaker Jazz Pharmaceuticals has inked an agreement with the USA’s Aerial BioPharma…

ADX-NO5Aerial BioPharmaGlobalJazz PharmaceuticalsLicensingNeurologicalPharmaceutical

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

13-01-2014

Based on positive Phase II data, US drug major Eli Lilly has acquired all development rights for a calcitonin…

Arteaus TherapeuticsEli LillyLicensingLY2951742NeurologicalPharmaceutical

NovaSAID partners with Cadila to develop inflammation and pain therapies

10-01-2014

Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

InteRNA Technologies, UCB and University of Bonn to collaborate on MicroRNAs in neurodegenerative disease

10-01-2014

Dutch pharma company InteRNA Technologies has entered into a collaboration with the Neuroallianz Consortium,…

NeurologicalNorthern EuropePharmaceuticalResearch

Adamas Pharma earns $40 milestone in Forest deal

10-01-2014

California, USA-based Adamas Pharmaceuticals revealed yesterday (January 9) that it has received $40…

Adamas PharmaceuticalsdonepezilFinancialForest LaboratoriesMDX-8704NamendaNeurologicalPharmaceuticalResearch

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

Added benefit of Sanofi’s Aubagio not proven, says IQWiG

08-01-2014

In yet another negative opinion from the German Institute for Quality and Efficiency in Health Care (IQWiG)…

AubagioGermanyNeurologicalNorthern EuropePharmaceuticalPricingRegulationSanofi

Neurocrine rockets on positive Phase II data for tardive dyskinesia treatment

08-01-2014

Shares of Neurocrine Biosciences were up almost 80% yesterday after it announced that NBI-98854, a small…

BiotechnologyNeurocrine BiosciencesNeurologicalResearchUSA

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

Ossianix in CNS research deal with Lundbeck

Ossianix in CNS research deal with Lundbeck

07-01-2014

Privately-held US firm Ossianix has announced a strategic research collaboration with Danish central…

LundbeckNeurologicalOssianixPharmaceuticalResearch

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

06-01-2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA,…

BrazilColoBreatheForest LaboratoriesLicensingMerck SeronoMoksha8NeurologicalPharmaceuticalRare diseasesRegulationSouth AmericaViibryd

AstraZeneca inks neuroscience collaboration with Lieber Institute

AstraZeneca inks neuroscience collaboration with Lieber Institute

04-01-2014

Anglo-Swedish drug major AstraZeneca has entered into a two-year research collaboration with the USA-based…

AstraZenecaNeurologicalPharmaceuticalResearch

73 to 97 of 914 results

Back to top